Earnings Call · Q2 FY2022·2022-08-06

Q2 22EPS +42.86%·Rev n/aQ1 22EPS +64.52%·Rev n/aQ4 21EPS -60.00%·Rev n/aQ3 21EPS 0.00%·Rev n/a⚠ consensus missing

Anika Therapeutics, Inc. ANIK

Mark Namaroff — Vice President of Investor Relations, ESG and Corporate Communications

Cheryl Blanchard — Chief Executive Officer

Michael Levitz — Chief Financial Officer

+2.3%1d on move date+0.8% vs SPY3d−6.0%5d−6.5%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ANIK calls or request research access.

More ANIK calls Browse calls Request research access